Large-cell neuroendocrine carcinoma of prostate. Case report

Archivos Espanoles de Urologia

Volumn 66, Issue 4, 2013, Pages 368-371

  Charcos, Luz Maria Moratalla ^a   Navarro, Teresa Pastor ^a   Vizcaino, Virginia Cortes ^a   Garcia, Jose Manuel Osca ^a   Salom, Manuel Gil ^a  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Neuroendocrine differentiation; Prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; TAXOID;

CARCINOMA, NEUROENDOCRINE; CASE REPORT; FATALITY; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; VERY ELDERLY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CARCINOMA, NEUROENDOCRINE; COMBINED MODALITY THERAPY; FATAL OUTCOME; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 84878657353     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Shah RB, Mehra R, Chinnaiyan, Shen R, Ghosh D, Zhou M y cols. Androgen-independent prostate cancer is a heterogeneus group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004; 64:9209-216. (Pubitemid 39665537)
2. Bohrer MH, Schmoll J. Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas. Verh Dtsch Ges Pathol. 1993; 77: 107-10.
3. di Sant' Agnese PA. Divergent neuroendocrine differentiation in prostatic carcinoma. Semin Diagn Pathol 2000; 17: 149-61. (Pubitemid 30322276)
4. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli, Kirkali Z, Montironi R. Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int 2008; 102(10):1369-74.
5. Rimoldi DA, Costa JA, Roveto S, Rivero O. Adenocarcinoma de próstata con diferenciación neuroendocrina de una variante a células pequeñas. Medicina (Buenos Aires) 2001; 61:322-24.
6. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006; 30(6):684-93. (Pubitemid 44264993)
7. Shariff AH, Ather MH. Neuroendocrine differentiation in prostate cancer. Urol, 2006; 68(1):2-8. Review. (Pubitemid 44037741)
8. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K ET AL. Cambios en los niveles plasmáticos de cromogranina A durante el tratamiento hormonal en pacientes con cáncer de próstata metastático. Eu Urol 2005; 48 (8): 224-30.
9. Ather MH, Abbas F, Faruqui N, Israr M, Prevés S. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Uirol. 2008; 30:8:21.
10. Feria-Bernal G, García-González VM, Figueroa-Granados V, Martínez-Benítez B, Uribe-Uribe NO. Diferenciación neuroendocrina y marcadores de proliferación celular en adenocarcinoma de próstata en un grupo de casos con antígeno prostático específico normal vs elevado. Gac Med Mex 2006; 142 (6): 441-46.
11. Kamiya N, Suzuki H, Kawamura K, Imamoto T, Naya Y, Tochigi N. Neuroendocrine differentiation in stage D2 prostate cancers. Int J Urol. 2008; 15(5):423-8. (Pubitemid 351623888)
12. NCCN Clinical practice Guidelines in Oncology 2009. Prostate cancer.